Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
Sign Up to like & getrecommendations! Published in 2019 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2018.10.005
Abstract: Introduction Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. Methods We performed a post hoc pooled efficacy and safety analysis that included HCV genotype 1–infected… read more here.
Keywords: ritonavir dasabuvir; ombitasvir paritaprevir; obv ptv; disease ... See more keywords
Drug–Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir–Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000000967
Abstract: Background: The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir–ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily. However,… read more here.
Keywords: prod; paritaprevir ritonavir; combination; csa ... See more keywords
Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C
Sign Up to like & getrecommendations! Published in 2017 at "Hepatology Research"
DOI: 10.1111/hepr.12910
Abstract: From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this… read more here.
Keywords: genotype chronic; efficacy safety; ombitasvir paritaprevir; paritaprevir ritonavir ... See more keywords
Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.12475
Abstract: Paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) is a direct‐acting antiviral (DAA) approved for the treatment of chronic hepatitis C virus. We report on a probable interaction between PrOD with ribavirin and warfarin. read more here.
Keywords: paritaprevir ritonavir; report; ritonavir ombitasvir; ombitasvir dasabuvir ... See more keywords
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.12917
Abstract: Paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for 12 weeks are approved for treatment of chronic HCV genotype 1 infection. This study assessed the efficacy of shortened duration paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin… read more here.
Keywords: ritonavir ombitasvir; ombitasvir dasabuvir; infection; paritaprevir ritonavir ... See more keywords
A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir
Sign Up to like & getrecommendations! Published in 2017 at "Case Reports in Gastroenterology"
DOI: 10.1159/000462965
Abstract: Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir… read more here.
Keywords: ombitasvir paritaprevir; paritaprevir ritonavir; therapy; interstitial pneumonia ... See more keywords
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial
Sign Up to like & getrecommendations! Published in 2020 at "BMC Infectious Diseases"
DOI: 10.1186/s12879-020-4921-3
Abstract: Background Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocellular carcinoma. Treatment with first generation protease inhibitors (PI) + peg-interferon (pegIFN) and ribavirin (RBV) achieved sustained virologic response (SVR) rates of… read more here.
Keywords: ritonavir dasabuvir; trial; ombitasvir paritaprevir; paritaprevir ritonavir ... See more keywords
Combined Use of Calcium-channel Blockers With Ombitasvir/Paritaprevir/Ritonavir Exacerbates Peripheral Edema in Elderly Japanese Patients
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15690
Abstract: Background/Aim: The antiviral agent ritonavir is a substrate for cytochrome P450 3A4 (CYP3A4); therefore, concomitant use of CYP3A4-metabolising drugs might cause adverse reactions to this drug. We investigated the plasma level of calcium channel blockers… read more here.
Keywords: peripheral edema; ombitasvir paritaprevir; ritonavir; channel blockers ... See more keywords
Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients.
Sign Up to like & getrecommendations! Published in 2018 at "Annals of hepatology"
DOI: 10.5604/01.3001.0012.7868
Abstract: INTRODUCTION AND AIM We assessed the characteristics of virological response to a combination treatment of ombitasvir, paritaprevir, and ritonavir in hepatitis C virus genotype 1-infected elderly Japanese patients. MATERIAL AND METHODS This multicenter prospective study… read more here.
Keywords: infected elderly; elderly japanese; ombitasvir paritaprevir; paritaprevir ritonavir ... See more keywords